In a column published by The Washington Post, an experimental weight-loss drug called retatrutide was shown in clinical trials to significantly ease painful knee osteoarthritis in people with obesity.
The Washington Post reported that retatrutide is currently completing its final round of clinical trials. The drug acts on three different hormone receptors in the body: GLP-1, GIP, and glucagon, earning it the nickname “triple G.” This differs from existing medications like semaglutide, which targets only GLP-1 receptors, and tirzepatide, which targets two.
Eli Lilly spotlighted fresh data on retatrutide at the American College of Rheumatology Convergence 2026 meeting.
“Weight reduction results in a reduction in the loading of the knee, which has previously been shown to be associated with a reduction in pain.”
said Thomas J. Schnitzer, MD, PhD, the lead study author and a professor of rheumatology at Northwestern University’s Feinberg School of Medicine in Chicago, in an interview with Everyday Health.
Retatrutide functions by mimicking three distinct natural hormones to slow digestion and reduce appetite. This multi-receptor activation drives substantial weight loss, which directly decreases mechanical stress on weight-bearing joints.
According to findings discussed on TODAY.com, the drug was evaluated in clinical results published in The England Journal of Medicine. Dr. Akshay Syal, an NBC medical contributor, explained the findings on the network and how they affect joint health and chronic pain management.
Researchers observed that participants taking retatrutide reported notable improvements in physical function alongside pain reduction. However, the trials also documented a higher frequency of gastrointestinal side effects among those receiving the active drug compared to the placebo group.
| Metric / Finding | Retatrutide Group | Placebo Group |
|---|---|---|
| Primary hormone receptors targeted | GLP-1, GIP, GCG (Triple G) | Varies (Single or Dual) |
| Most common adverse events | Nausea, diarrhea, constipation |
Obesity creates a chronic, low-grade inflammatory state throughout the body. While weight loss remains the primary driver of joint relief, experts suggest secondary anti-inflammatory changes may also contribute.
Schnitzer told Everyday Health that it remains unclear whether additional mechanisms are involved. “Whether there are other mechanisms involved in reducing pain, such as anti-inflammatory effects related to a reduction in fat mass or the drug were not studied and are not known,” he said.
Gastrointestinal side effects led some participants to discontinue use during the studies. Gastrointestinal symptoms such as nausea, diarrhea, and constipation occurred more frequently in patients taking retatrutide than in those on a placebo.
Physicians emphasize that retatrutide does not replace standard arthritis care. Comprehensive treatment plans still require muscle strengthening, low-impact physical activity, and targeted nutritional guidance.
Questions remain regarding whether the drug will offer similar benefits to patients with knee osteoarthritis who do not have obesity. Schnitzer said that this specific demographic has not yet been studied and warrants further clinical investigation.
- The Washington Post: Column coverage on retatrutide and knee osteoarthritis.
- Everyday Health: Clinical trial pool analysis and expert commentary.
- TODAY.com: Broadcast coverage detailing The England Journal of Medicine findings.
- Eli Lilly: Data presented at the ACR Convergence 2026 meeting.
